CrossrefInfokarte
Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?
European Journal of Cancer · 2026-12 · 249 · 117808
DOI: 10.1016/j.ejca.2026.117808 ↗Abstract
Kein Abstract verfügbar.
EUVIMED